{
    "clinical_study": {
        "@rank": "141411", 
        "arm_group": [
            {
                "arm_group_label": "empagliflozin high dose", 
                "arm_group_type": "Experimental", 
                "description": "Patient to receive a high dose of empagliflozin"
            }, 
            {
                "arm_group_label": "empagliflozin medium dose", 
                "arm_group_type": "Experimental", 
                "description": "Patient to receive a medium dose of empagliflozin"
            }, 
            {
                "arm_group_label": "empagliflozin low dose", 
                "arm_group_type": "Experimental", 
                "description": "Patient to receive a low dose of empagliflozin"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to generate pharmacokinetic and pharmacodynamic data to identify the\n      safe-effective dose of empagliflozin in children and adolescents aged 10 to less than 18\n      years with type 2 diabetes mellitus."
        }, 
        "brief_title": "Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Children and adolescents with type 2 diabetes mellitus\n\n          -  Insufficient glycaemic control (6.5% < HbA1c > 10.5%) despite diet and exercise\n             and/or metformin\n\n          -  Negative for Islet Cell Antigen and Glutamic Acid Decarboxylase autoantibodies and\n             fasting C-peptide levels >= 0.85 ng/ml\n\n          -  BMI > 50th percentile for age and sex\n\n        Exclusion criteria:\n\n          -  Uncontrolled hyperglycaemia with a glucose level > 240 mg/dl (> 13.3 mmol/l)\n\n          -  History of acute metabolic decompensation such as diabetic ketoacidosis within 3\n             months before screening\n\n          -  Current insulin therapy or having received insulin within 4 weeks before\n             randomisation\n\n          -  Treatment with weight reduction medications within 4 weeks before randomisation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02121483", 
            "org_study_id": "1245.87", 
            "secondary_id": "2013-002304-14"
        }, 
        "intervention": [
            {
                "arm_group_label": "empagliflozin medium dose", 
                "intervention_name": "empagliflozin medium dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "empagliflozin high dose", 
                "intervention_name": "empagliflozin high dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "empagliflozin low dose", 
                "intervention_name": "empagliflozin low dose", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Wien", 
                        "country": "Austria"
                    }, 
                    "name": "1245.87.43001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France"
                    }, 
                    "name": "1245.87.33001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "1245.87.49001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "France", 
                "Germany"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-label, Randomised, Multicentre, Single-dose, Parallel Group Trial to Evaluate Pharmacokinetics and Pharmacodynamics of Empagliflozin in Children and Adolescents From 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Austria: Austrian Medicines and Medical Devices Agency", 
                "Canada: Health Canada", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Israel: Israeli Health Ministry Pharmaceutical Administration", 
                "Mexico: Federal Commission for Sanitary Risks Protection", 
                "South Africa: Medicines Control Council", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC0-infinity (Area under the plasma concentration-time curve from time zero to infinite time)", 
                "safety_issue": "No", 
                "time_frame": "up to Day 3"
            }, 
            {
                "measure": "AUC0-tz (Area under the plasma concentration-time curve from time zero to the the time of the last quantifiable concentration)", 
                "safety_issue": "No", 
                "time_frame": "up to Day 3"
            }, 
            {
                "measure": "Cmax (Maximum observed plasma concentration)", 
                "safety_issue": "No", 
                "time_frame": "up to Day 3"
            }, 
            {
                "measure": "tmax (Time of maximum observed plasma concentration)", 
                "safety_issue": "No", 
                "time_frame": "up to Day 3"
            }, 
            {
                "measure": "t1/2 (Terminal half-life in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to Day 3"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02121483"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in urinary glucose excretion", 
                "safety_issue": "No", 
                "time_frame": "over 24 hours after study drug intake"
            }, 
            {
                "measure": "Change from baseline in fasting plasma glucose (mg/dL)", 
                "safety_issue": "No", 
                "time_frame": "24 hours after study drug intake"
            }, 
            {
                "measure": "Change from baseline in 8-point plasma glucose profile", 
                "safety_issue": "No", 
                "time_frame": "over 24 hours after study drug intake"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "collaborator": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}